Skip to main content

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy

Ziel

This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project.

The preceding Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by the combination of intracellular drug delivery and magnetic hyperthermia. In particular, some of the designed formulations (patent filed PCT/EP2015/056631) have proven their efficacy, safety and non-toxicicty, in in vitro and in vivo studies, against the mentioned cancers, thus making them promising candidates to produce a novel nanomedicine therapy for cancer.

NoCanTher aims at translating one of these nanoformulations to early clinical development for pancreatic cancer. Particularly, we plan to assess bare nanoparticles (System B) and multifunctional nanoparticles (System A) in advanced preclinical models and run a clinical study with the System B. To successfully reach this objective, we will concentrate our efforts in two main group of activities:

• Nanotherapeutic up-scaling under Certfified conditions: NoCanTher will scale up the manufacturing of the proposed nanoformulation from milligram-scale laboratory synthesis up to multigram-scale production to generate sufficient material for clinical and regulatory assays. To this aim, a certified production line will be optimised and the relevant quality control will be conducted at the different stages of the up-scaling process.
• Clinical Study: NoCanTher will include late preclinical parameter testing to raise a clinical treatment protocol, regulatory assays, as well as the design of the clinical study and the preparation of the Investigational Medicinal Device Dossier (IMDD).

This strategy will allow us to apply for Clinical Study Authorisation (CSA) then, we will carry out a Clinical Study. NoCanTher involves the participation of 11 institutions from three different sectors (academia, industry, clinical) and from five different countries (Ireland, France, Germany, Spain and the UK).

Aufforderung zur Vorschlagseinreichung

H2020-NMP-2015-two-stage
Andere Projekte für diesen Aufruf anzeigen

Koordinator

FUNDACION IMDEA NANOCIENCIA
Adresse
Calle Faraday 9 Ciudad Universitaria De Cantoblanco
28049 Madrid
Spanien
Aktivitätstyp
Research Organisations
EU-Beitrag
€ 729 696,89

Beteiligte (11)

BIOKERALTY RESEARCH INSTITUTE AIE
Spanien
EU-Beitrag
€ 1 494 864,37
Adresse
Entidad Arcaute 005 Arcaute
01192 Arcaute Alava
Aktivitätstyp
Other
IMMUPHARMA PLC
United Kingdom
EU-Beitrag
€ 175 250,21
Adresse
50 Broadway
SW1H 0RG London
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
CHEMICELL GMBH
Deutschland
EU-Beitrag
€ 174 171
Adresse
Eresburgstrasse 22-23
12103 Berlin
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III

Beteiligung beendet

Spanien
EU-Beitrag
€ 88 538,36
Adresse
C Melchor Fernandez Almagro 3
28029 Madrid
Aktivitätstyp
Research Organisations
UNIVERSITATSKLINIKUM JENA
Deutschland
EU-Beitrag
€ 755 768,05
Adresse
Kastanienstr.1
07747 Jena
Aktivitätstyp
Higher or Secondary Education Establishments
RESONANT CIRCUITS LIMITED
United Kingdom
EU-Beitrag
€ 888 684,93
Adresse
Albermale Street The Royal 21
W1S 4BS London
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA
Spanien
EU-Beitrag
€ 630 633,55
Adresse
Passeig Vall D Hebron 119-129 Edificio De Recerca
08035 Barcelona
Aktivitätstyp
Research Organisations
THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Irland
EU-Beitrag
€ 671 039,54
Adresse
College Green
2 Dublin
Aktivitätstyp
Higher or Secondary Education Establishments
UNIVERSITE DE PARIS
Frankreich
EU-Beitrag
€ 603 527,89
Adresse
85 Bd Saint Germain
75006 Paris
Aktivitätstyp
Higher or Secondary Education Establishments
FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Spanien
EU-Beitrag
€ 347 979,26
Adresse
Calle Nazaret 115-117
08035 Barcelona
Aktivitätstyp
Research Organisations
HOSPITAL UNIVERSITARIO DE FUENLABRADA
Spanien
EU-Beitrag
€ 553 624,70
Adresse
Calle Del Molino 2
28942 Fuenlabrada
Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)